The HIV protease inhibitor lopinavir/ritonavir (Kaletra) alters the growth, differentiation and proliferation of primary gingival epithelium

HIV Medicine

Volumn 12, Issue 3, 2011, Pages 145-156

  Israr, M ^a   Mitchell, D ^a   Alam, S ^a   Dinello, D ^b   Kishel, J J ^a   Meyers, C ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b Oral Surgery Associates   (United States)

Author keywords

Antiretroviral therapy; Cytokeratins; HIV infections; Lopinavir ritonavir; Oral complications

Indexed keywords

CYCLIN A; CYCLINE; CYTOKERATIN 10; CYTOKERATIN 14; CYTOKERATIN 5; CYTOKERATIN 6; EOSIN; HEMATOXYLIN; LOPINAVIR PLUS RITONAVIR;

ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; DRUG EFFECT; GINGIVA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MAXIMUM PLASMA CONCENTRATION; MUCOSA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE GROWTH; TRANSMISSION ELECTRON MICROSCOPY;

CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; EPITHELIAL CELLS; EPITHELIUM; GINGIVA; HIV PROTEASE INHIBITORS; HUMANS; KERATINOCYTES; MICROSCOPY, ELECTRON, TRANSMISSION; PYRIMIDINONES; RITONAVIR;

EID: 78650226707     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2010.00863.x     Document Type: Article

References (51)

1. Global summary of the AIDS epidemic. The Joint United Nations Programme on HIV AIDS (UNAIDS). November, 2009. Available at (accessed 22 February 2010).
2. Gortmaker SL, Hughes M, Cervia J et al. Effects of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med 2001; 345: 1522-1528.
3. Granados JMS, Amador JTR, De Miguel SF et al. Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus infected children. Pediatr Infect Dis J 2003; 22: 863-867.
4. Patton LL, McKaig R, Strauses R, Rogers D, Eron JJ Jr. Changing prevalence of oral manifestations of human immunodeficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 89: 299-304.
5. Greenspan D, Canchola AJ, MacPhail A, Cheikh B, Greenspan JS. Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet 2001; 357: 1411-1412.
6. Greenspan JS, Greenspan D. The epidemiology of the oral lesions of HIV infection in the developed world. Oral Dis 2002; 8: 34-39.
7. Hodgson TA, Greenspan D, Greenspan JS. Oral lesions of HIV disease and HAART in industrialized countries. Adv Dent Res 2006; 19: 57-62.
8. Scully C, Diz Dios P. Orofacial effects of antiretroviral therapies. Oral Dis 2001; 7: 205-210.
9. Diz Dios P, Scully C. Adverse effects of antiretroviral therapy: focus on orofacial effects. Expert Opin Drug Saf 2002; 1: 307-317.
10. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, Naldi L, Viboud C, Roujeau JC. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001; 15: 1843-1848.
11. Jordan RA. Implications of antiretroviral therapy in oral medicine-a review of literature. Schw Mont f Zahn 2007; 117: 1210-1216.
12. Hawkins T. HIV drug resistance and you. The limitations of drug resistance testing. Many factors influence the results. Posit Aware 2006; Winter issue: 13-16.
13. Chandwani A, Shutter J. Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manage 2008; 4: 1023-1033.
14. Lee CA, Mistry D, Sharma R, Coatesworth AP. Rhinological, laryngological, oropharyngeal and other head and neck side effects of drugs. J Laryngol Otol 2006; 120: 1-10.
15. Borras-Blasco J, Navarro-Ruiz A, Borras C, Castera E. Adverse Cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J Antimicrob Chemother 2008; 62: 879-888.
16. HIV and oral health. Appendix 1: selected agents used to treat HIV infection or related conditions. June, 2006. Available at (accessed 10 February 2010).
17. Presland RB, Dale BA. Epithelial structural proteins of the skin and oral cavity: function in health and disease. Crit Rev Oral Biol Med 2000; 11: 383-408.
18. Sun TT, Eichner R, Schermer A, Cooper D, Nelson WG, Weiss RA. Classification, expression and possible mechanisms of evolution of mammalian epithelial keratins: a unifying model, In: Levine AJ, Vande Woude GF, Topp WC, Watson JD, eds. The Transformed Phenotype: Cancer Cells. New York: Cold Spring Harbor Laboratory, 1984: 169-176.
19. Garrod D, Chidgey M. Desmosome structure, composition and function. Biochim Biophys Acta 2008; 1778: 572-587.
20. Israr M, Mitchel D, Alam S, Dinello D, Kishel JJ, Meyers C. Effect of the HIV protease inhibitor Amprenavir on the growth and differentiation of primary gingival epithelium. Antivir Ther 2010; 15: 253-265.
21. Meyers C, Frattini MG, Hudson JB, Laimins LA. Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science 1992; 257: 971-973.
22. Meyers C. Organotypic (raft) epithelial tissue culture system for the differentiation dependent replication of papillomavirus. Meth Cell Sci 1996; 18: 1-10.
23. Rolinski B, Wintergerst U, Matuschke A et al. Evaluation of saliva as a specimen for monitoring zidovudine therapy in HIV-infected patients. AIDS 1991; 5: 885-888.
24. Drummer OH. Drug testing in oral fluid. Clin Biochem Rev 2006; 27: 147-159.
25. Rakhmanina NY, Capparelli EV, van den Anker JN et al. Nevirapine concentration in nonstimulated saliva: an alternative to plasma sampling in children with human immunodeficiency virus infection. Ther Drug Monit 2007; 29: 110-117.
26. Tomakidi P, Fusenig NE, Kohl A, Komposch G. Histomorphological and biochemical differentiation capacity in organotypic co-cultures of primary gingival cells. J Periodontal Res 1997; 32: 388-400.
27. Klausner M, Ayehunie S, Breyfogle BA, Wertz PW, Bacca L, Kubilus J. Organotypic human oral tissue models for toxicological studies. Toxicol In Vitro 2007; 21: 938-949.
28. Mackenzie IC, Rittman G, Gao Z, Leigh I, Lane EB. Patterns of cytokeratin expression in human gingival epithelia. J Periodontal Res 1991; 26: 468-478.
29. Eichner R, Bonitz P, Sun TT. Classification of epidermal keratins according to their immunoreactivity, isoelectric point, and mode of expression. J Cell Biol 1984; 96: 1388-1396.
30. Purkis PE, Steel JB, Mackenzie IC, Nathrath WB, Leigh IM, Lane EB. Antibody markers of basal cells in complex epithelia. J Cell Sci 1990; 97: 39-50.
31. Bonan PRF, Kaminagakura E, Pires FR. Cytokeratin expression in initial oral mucositis of head and neck irradiated patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101: 205-211.
32. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982; 31: 11-24.
33. Bloor BK, Seddon SV, Morgan PR. Gene expression of differentiation specific keratins (K4, K13, K1 and K10) in oral non-dysplastic keratoses and lichen planus. J Oral Pathol Med 2000; 29: 376-384.
34. Santos JN, Sousa SO, Nunes FD, Sotto MN, De Araujo VC. Altered cytokeratin expression in actinic cheilitis. J Cutan Pathol 2003; 30: 237-241.
35. Bloor BK, Tidman N, Leigh IM et al. Expression of keratin K2e in cutaneous and oral lesions: association with keratinocytes activation, proliferation and keratinization. Am J Pathol 2003; 162: 963-975.
36. Wetzels RH, Kujipers HJ, Lane EB et al. Basal specific and hyperproliferation-related keratins in human breast cancer. Am J Pathol 1991; 138: 751-763.
37. Morgan PR, Su L. Intermediate filaments in oral neoplasia. 1. Oral cancer and epithelial dysplasia. Eur J Cancer B Oral Oncol 1994; 30B: 160-166.
38. Usui ML, Underwood RA, Mansbridge JN, Muffley LA, Carter WG, Olerud JE. Morphological evidence for the role of suprabasal keratinocytes in wound reepithelialization. Wound Rep Reg 2005; 13: 468-479.
39. Paladini RD, Takahashi K, Bravo NS, Coulombe PA. Onset of re-epithelialization after skin injury correlates with a reorganization of keratin filaments in wound edge keratinocytes: defining a potential role for keratin 16. J Cell Biol 1996; 132: 381-397.
40. Weiss RA, Eichner R, Sun TT. Monoclonal antibody analysis of keratin expression in epidermal diseases: a 48 and 56-kdalton keratin as molecular marker for hyperproliferative keratinocytes. J Cell Biol 1984; 98: 1397-1406.
41. Mansbridge JN, Knapp AM. Changes in keratinocytes maturation during wound healing. J Invest Dermatol 1987; 89: 253-263.
42. Stoler A, Kopan R, Duvic M, Fuchs E. Use of monospecific antisera and cRNA probes to localize the major changes in keratin expression during normal and abnormal epidermal differentiation. J Cell Biol 1988; 107: 427-446.
43. Lundqvist K, Schmidtchen A. Cyclin A expression in chronic leg ulcers. Acta Derm Venereol 2006; 86: 61-62.
44. Thompson PJ, Goodson ML, Booth C, Cragg N, Hamadah O. Cyclin A activity predicts clinical outcome in oral precancer and cancer. Int J Oral Maxillofac Surg 2006; 35: 1041-1046.
45. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G. Cyclin A is required at two points in the human cell cycle. EMBO J 1992; 11: 961-971.
46. Celis JE, Celis A. Cell cycle dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase. Proc Natl Acad Sci USA 1985; 82: 3262-3266.
47. Zuber M, Tan EM, Ryoji M. Involvement of proliferating cell nuclear antigen (cyclin) in DNA replication in living cells. Mol Cell Biol 1989; 9: 57-66.
48. Bujia J, Sudhoff H, Holly A, Hildmann H, Kastenbauer E. Immunohistochemical detection of proliferating cell nuclear antigen in middle ear cholesteatoma. Eur Arch Otorhinolaryngol 1996; 253: 21-24.
49. Girod SC, Pfeiffert P, Ries J, Papet HD. Proliferative activity and loss of function of tumour suppressor genes as biomarkers in diagnosis and prognosis of benign and preneoplastic oral lesions and oral squamous cell carcinoma. Br J Oral Maxillofac Surg 1998; 36: 252-260.
50. King MD, Reznik DA, O'Daniela CM, Larsen NM, Osterholt D, Blumberg HM. Human papillomavirus associated oral warts among human immunodeficiency virus seropositive patients in the area of highly active antiretroviral therapy: an emerging infection. Clin Infect Dis 2002; 34: 641-648.
51. Cameron JE, Mercante D, O'Brien M et al. The impact of highly active antiretroviral therapy and immunodeficiency on human papillomavirus infection of the oral cavity of human immunodeficiency virus seropositive adults. Sex Transm Dis 2005; 32: 703-709.